Related Experiment Video
Updated: May 24, 2026

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
[Inhaled therapies for cystic fibrosis].
Samir Lahzami1, Laurent P Nicod
1Service de pneumologie, Département de médecine, CHUV, 1011 Lausanne. Samir.Lahzami@chuv.ch
Inhaled therapies are crucial for cystic fibrosis management, improving lung function and reducing toxicity. Newer nebulizer technologies enhance treatment efficiency and patient adherence.
Area of Science:
- Pulmonology and Respiratory Medicine
- Pharmacology and Therapeutics
Context:
- Cystic Fibrosis (CF) management relies heavily on inhaled medications.
- Current inhaled therapies include mucolytics, airway rehydrators, and antibiotics.
- Nebulization is the primary delivery method due to liquid formulations.
Purpose:
- To review the role and efficacy of inhaled therapies in cystic fibrosis.
- To discuss the benefits and limitations of various inhaled agents.
- To highlight advancements in nebulizer technology.
Summary:
- Inhaled mucolytics and rehydrating agents enhance mucociliary clearance and respiratory function in CF patients.
- Nebulized antibiotics provide high local drug concentrations, minimizing systemic side effects.
- Bronchoconstriction is a common side effect, manageable with beta2-agonists.
- Vibrating-mesh nebulizers have notably decreased treatment duration.
Impact:
- Optimized inhaled therapy regimens can significantly improve quality of life for CF patients.
- Technological advancements in nebulizers enhance treatment adherence and effectiveness.
- High local antibiotic concentrations may combat respiratory infections more effectively with reduced systemic exposure.
More Related Videos
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
07:38Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
Published on: August 3, 2021
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Inhaled Medications
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
COPD: Management Using Bronchodilators and Corticosteroids